Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

New milestone cash inflow completes expected 2026 proceeds from the Vivasure sale and may support Orchestra BioMed’s pivotal device programs.

Rhea-AI Summary

Orchestra BioMed (OBIO) received a $6.1 million milestone payment on September 14, 2026, tied to Haemonetics’ acquisition of Vivasure Medical. This follows an approximately $5 million upfront payment in January 2026, bringing total cash proceeds from the transaction in 2026 to approximately $11 million, which completes the amount previously expected for this year.

The company remains eligible for up to approximately $10 million in additional revenue-based earnout payments, for total potential proceeds of up to $21 million. Vivasure had been a strategic holding of Orchestra BioMed since the company’s formation. Management states that monetizing this holding provides incremental capital to advance its pivotal programs, including AVIM Therapy for uncontrolled hypertension and the Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease.

Positive

• $6.1 million milestone payment received on September 14, 2026
• Total 2026 cash proceeds from Vivasure deal now approximately $11 million
• Eligible for up to an additional $10 million in future revenue earnouts
• Total potential proceeds from Vivasure transaction up to $21 million
• Management plans to use proceeds to support pivotal AVIM and Virtue SAB programs

Negative

• None.

Market Context

The $6.1 million milestone payment extended the Vivasure transaction proceeds reported in January; t...

Analysis

The $6.1 million milestone payment extended the Vivasure transaction proceeds reported in January; that earlier acquisition-proceeds announcement was followed by a 2.92% decline over 24 hours.

Key Figures

Milestone payment: $6.1 million Prior upfront payment: Approximately $5 million Total cash proceeds received: Approximately $11 million +2 more

Milestone payment

$6.1 million

Received September 14, 2026

Prior upfront payment

Approximately $5 million

Received January 2026

Total cash proceeds received

Approximately $11 million

From the Vivasure-Haemonetics transaction

Additional earnout proceeds

Up to approximately $10 million

Subject to future revenue milestones

Total potential proceeds

Up to $21 million

Including future revenue earnouts

Previous Acquisition Reports

2 past events · Latest: Jan 12

Same Type 2 events

1. Jan 12

   Acquisition proceeds

   24h Move

   -2.9%

   Initial Vivasure acquisition proceeds included upfront cash and milestone payment expectations.

2. Jan 09

   Vivasure acquisition

   24h Move

   -0.8%

   Haemonetics announced Vivasure acquisition with milestone-based consideration and FDA filing context.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

revenue earnouts, arteriotomies, venotomies, breakthrough device designation

4 terms

revenue earnouts financial

"additional proceeds through future revenue earnouts"

Revenue earnouts are contingent payments built into a sale or merger agreement where the buyer agrees to pay the seller additional money later if the acquired business achieves specified future revenue targets. They matter to investors because they change the effective purchase price, shift risk between buyer and seller, and affect expected future cash flows and accounting disclosures; think of them like a performance bonus the seller only receives if sales reach agreed milestones.

arteriotomies medical

"seal large-bore arteriotomies and venotomies from inside the vessel"

An arteriotomy is a surgical cut made into an artery to gain access for procedures like placing catheters, stents, or performing repairs. For investors, the prevalence and safety of arteriotomies affect demand for closure devices, surgical tools and consumables because these cuts carry bleeding and infection risks and require reliable ways to seal the artery—like making a doorway in a water pipe that must be securely closed afterward.

venotomies medical

"seal large-bore arteriotomies and venotomies from inside the vessel"

A venotomy is a medical procedure that involves making a small cut into a vein to gain direct access for treatment, such as inserting a catheter, removing a clot, or taking a tissue sample. It matters to investors because the need for venotomies drives demand for surgical tools, catheters and clot-removal devices and can affect hospital procedure volumes, device company revenues, and regulatory scrutiny tied to patient safety and outcomes—similar to how a repair opening enables a mechanic to fix a car and shapes sales of shop tools.

breakthrough device designation regulatory

"AVIM Therapy has FDA Breakthrough Device Designations"

A breakthrough device designation is a regulatory program that gives promising medical devices for serious or life‑threatening conditions priority support and faster review from a health authority (e.g., the U.S. FDA). Think of it as a “fast lane” or VIP pass through development and review: it can shorten time to market, lower regulatory uncertainty, and boost a company’s commercial prospects — but it is not an approval by itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
• Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
• Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships
  
  

NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of $6.1 million on September 14, 2026, as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical Limited (“Vivasure”) by Haemonetics Corporation (NYSE: HAE, “Haemonetics”). This second payment follows the approximately $5 million upfront payment received in January 2026 and brings total cash proceeds received by Orchestra BioMed from the transaction to approximately $11 million.

Vivasure, an Ireland-based company pioneering next-generation technology for percutaneous vessel closure, had been a strategic holding of Orchestra BioMed since the Company’s formation. Haemonetics completed its acquisition of Vivasure on January 9, 2026, as previously announced.

The payment completes the approximately $11 million in proceeds previously disclosed as expected during 2026. Orchestra BioMed remains eligible to receive up to approximately $10 million in additional proceeds through future revenue earnouts, subject to the achievement of certain milestones, for total potential proceeds of up to $21 million.

Developed by Vivasure, the PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. PerQseal Elite is not available for sale in the United States.

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue^® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

About Haemonetics

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Haemonetics’ innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com

Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What triggered the new $6.1 million payment to Orchestra BioMed?

The $6.1 million received on September 14, 2026, is described as the first milestone payment under the agreement related to Haemonetics’ acquisition of Vivasure Medical. It follows a previously received upfront payment and is part of the overall transaction structure tied to that acquisition.

How much additional money can Orchestra BioMed potentially receive from the Vivasure transaction?

Beyond the approximately $11 million already received, Orchestra BioMed remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts. If all earnout milestones are achieved, total potential proceeds from the Vivasure transaction could reach up to $21 million.

How does Orchestra BioMed plan to use the proceeds from the Vivasure monetization?

The company states that monetization of the Vivasure holding provides additional capital to advance its pivotal programs. These include its flagship product candidates, AVIM Therapy for uncontrolled hypertension and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for atherosclerotic artery disease.

What are Orchestra BioMed’s flagship product candidates mentioned in the announcement?

The company highlights two flagship candidates: AVIM Therapy, a pacemaker-delivered bioelectronic treatment for hypertension with FDA Breakthrough Device Designations, and Virtue SAB, a non-coated drug delivery angioplasty balloon using a proprietary extended-release sirolimus formulation (SirolimusEFR) for atherosclerotic artery disease. Both are undergoing pivotal clinical trials for their lead indications.